Clinical trial NCT00434226: A Study of Sunitinib in Combination With Bevacizumab, Carboplatin, and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer (SABRE-L)
Official title: A Randomized, Controlled, Open-Label, Multicenter, Phase II Study of the Safety and Efficacy of Sunitinib in Combination With Bevacizumab, Carboplatin, and Paclitaxel in Previously Untreated Patients With Advanced Non-Small Cell Lung Cancer
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Non-Small Cell Lung Cancer
Keywords: SABER-L
NSCLC
Avastin
Sutent
Lead sponsor: Genentech, Inc.
Sponsor class: INDUSTRY
First posted: 2007-02-13
Enrollment: 56
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a Phase II, randomized, controlled, open-label, multicenter trial designed to provide a preliminary assessment of the safety and efficacy of sunitinib when combined with carboplatin and paclitaxel chemotherapy and bevacizumab in patients with locally advanced, recurrent or metastatic NSCLC who have not received prior systemic therapy for NSCLC. All patients will have advanced, histologically or cytologically confirmed NSCLC (Stage IIIb with pleural effusions, Stage IV, or recurrent).


Eligibility criteria: Inclusion Criteria:

* Signed Informed Consent Form
* Age ≥ 18 years
* Advanced histologically or cytologically confirmed NSCLC (Stage IIIb with malignant pleural or pericardial effusion, Stage IV, or recurrent)
* Measurable or non-measurable disease
* Patients with treated brain metastases are eligible if there is no evidence of progression or hemorrhage after treatment, as ascertained by clinical examination and brain imaging (MRI or CT) during the screening period (brain imaging to be competed Day -7 to Day 1).
* Prior treatment for CNS disease as deemed appropriate by the treating physician
* ECOG performance status 0 or 1
* Ability and willingness to comply with study and follow-up procedures

Exclusion Criteria:

* Prior systemic chemotherapy for metastatic disease
* Active malignancy other than lung cancer
* Current, recent, or planned participation in another experimental drug study
* Prior treatment with anti-VEGF agent or agents targeting similar pathways as sunitinib
* Adjuvant chemotherapy or prior combined modality neoadjuvant therapy (chemotherapy plus radiotherapy with or without surgery) within 6 months prior to Day 1 of Cycle 1
* Life expectancy of \< 12 weeks
* Current, recent, or planned participation in an experimental drug study
* Inability to take oral medication or requirement of IV alimentation or total parenteral nutrition, or prior surgical procedures affecting absorption
* Inadequate organ function
* Known evidence of disseminated intravascular coagulopathy
* Active infection or fever \> 38.5°C within 3 days prior to Day 1 of Cycle 1
* Untreated abnormal thyroid function tests as defined by institutional standards (patients with controlled hypothyroidism are eligible for study participation)
* Any other medical condition(s) (including mental illness or substance abuse) deemed by the clinician to be likely to interfere with a patient's ability to provide informed consent, cooperate, or participate in the study, or to interfere with the interpretation of the results
* Intrathoracic lung carcinoma of squamous cell histology
* Known CNS disease except for treated brain metastases
* Inadequately controlled hypertension
* Prior history of hypertensive crisis or hypertensive encephalopathy
* New York Heart Association (NYHA) Class II or greater CHF
* History of myocardial infarction or unstable angina within 12 months prior to Day 1 of Cycle 1
* History of stroke or transient ischemic attack within 12 months prior to Day 1 of Cycle 1
* Significant vascular disease (e.g., aortic aneurysm, aortic dissection) or recent peripheral arterial thrombosis within 6 months prior to Day 1 of Cycle 1
* History of hemoptysis within 1 month prior to Day 1 of Cycle 1
* Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
* Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 1 of Cycle 1 or anticipation of need for major surgical procedure during the course of the study
* Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to Day 1 of Cycle 1
* History of abdominal fistula or gastrointestinal perforation within 6 months prior to Day 1 of Cycle 1
* Serious, non-healing wound, active ulcer, or untreated bone fracture
* Proteinuria at screening, as demonstrated by a urine protein/creatinine ratio of ≥ 1.0 at screening
* Known hypersensitivity to any component of bevacizumab or sunitinib
* Pregnancy (positive pregnancy test) or lactation

Primary outcomes:
measure: Best Response
timeFrame: From randomization until disease progression/recurrence
Secondary outcomes:
measure: Serious Adverse Events
timeFrame: 60 days following the last administration of study treatment
measure: Incidence of Grade ≥ 3 Adverse Events
timeFrame: 60 days following the last administration of study treatment
measure: Incidence of Adverse Events Leading to Sunitinib Discontinuation, Dose Interruption, or Dose Reduction
timeFrame: 60 days following the last administration of study treatment
measure: Incidence of Adverse Events Leading to Bevacizumab Discontinuation or Dose Interruption
timeFrame: 60 days following the last administration of study treatment
Other outcomes:
Locations:
Study officials:
affiliation: Genentech, Inc.
name: Julie Hambleton, M.D.
role: STUDY_DIRECTOR
References: